Back to Search
Start Over
[S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].
- Source :
-
Zeitschrift fur Rheumatologie [Z Rheumatol] 2018 Jun; Vol. 77 (5), pp. 429-441. - Publication Year :
- 2018
-
Abstract
- Polymyalgia rheumatica (PMR) occurs almost exclusively in persons aged 50 years or older and it is the second most common inflammatory rheumatic disease in older people after rheumatoid arthritis. Since there are no specific tests for PMR, the exclusion of clinically similar differential diagnoses is essential to ascertain the diagnosis. These recommendations for the management of PMR assume an already established diagnosis of PMR. It is recommended to initiate treatment with glucocorticoids immediately after diagnosis and to provide appropriate patient information and education about the impact of the disease and its treatment. Methotrexate should be considered in patients at high risk for relapse and/or glucocorticoid-related adverse events. These guidelines have been elaborated because there is significant heterogeneity in the management of PMR in clinical practice in Germany (but also Europe and worldwide), despite the large number of patients with this disease. These guidelines are primarily based on the 2015 EULAR-ACR recommendations for the management of PMR, which were updated by the guideline committee and adapted to the German speaking countries.
Details
- Language :
- German
- ISSN :
- 1435-1250
- Volume :
- 77
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Zeitschrift fur Rheumatologie
- Publication Type :
- Academic Journal
- Accession number :
- 29845555
- Full Text :
- https://doi.org/10.1007/s00393-018-0476-8